FDA Launches Year Four of Drug Speed-Up Pilot Program
Published Date: 8/28/2025
Notice
Summary
The FDA is kicking off year four of its Chemistry, Manufacturing, and Controls Development and Readiness Pilot to help drug makers speed up getting important new medicines ready for patients. This program boosts teamwork between the FDA and drug developers, using smart, science-based ways to fast-track drug testing and production. If you’re making a new drug with a fast timeline, now’s the time to apply and get extra support!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Pilot speeds CMC readiness for sponsors
The FDA announced year four of the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP). If you are a drug developer with a product under an investigational new drug application (IND), the pilot helps expedite chemistry, manufacturing, and controls (CMC) development based on the anticipated clinical benefit of earlier patient access.
Targets CBER and CDER regulated products
The pilot applies to products regulated by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. Sponsors of biologics and drugs on accelerated timelines are the intended participants for this program.
More FDA‑sponsor communication and approaches
The pilot features increased communication between FDA and sponsors and explores science- and risk-based regulatory approaches to accelerate CMC development and readiness. That means sponsors accepted into the pilot may get extra dialogue and use of risk-based methods with FDA reviewers.
Could speed earlier patient access to drugs
The pilot is intended to facilitate expedited CMC development when there is an anticipated clinical benefit of earlier patient access to products. That means some patients may get access to new medicines sooner if their developers participate in the pilot.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-16512, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; BIS Program Evaluation
The Bureau of Industry and Security (BIS) is renewing its survey that collects feedback from businesses attending export control seminars. This helps BIS improve its training programs without adding much time or hassle—each survey takes just 10 minutes and is totally voluntary. Over 3,000 businesses might join in, and the public has 30 days to share their thoughts before the renewal is finalized.
Next: 2025-16514, Patient-Focused Drug Development: Workshop #2 To Discuss Methodologic and Other Challenges Related to Patient Experience Data; Public Workshop; Request for Comments
The FDA is hosting a fun and important workshop to tackle tricky questions about how to collect and use patient experience data when developing new medicines. This event helps patients, drug makers, and doctors work together to make treatments better and more patient-friendly. If you care about medicine that fits real people’s needs, this is your chance to join the conversation and shape the future!